Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A33: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (Japan, Phase 1)
jRCT2080225167Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Merck & Co. Primary endpoints: Objective response rate (ORR) by independent central review and Disease control rate (DCR) by independent central review. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT2080225167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225167.